Circadian Rhythm Stabilization App to Prevent Mood Episode Recurrence in Patients With Mood Disorders: A Multicenter, Double-Blind, Sham-Controlled, Randomized Clinical Trial.

Am J PsychiatryJun 24, 2026 (epub)
Clinical ResearchPsychiatry

Ji Won Yeom, Jaegwon Jeong, Eunsoo Moon et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter, double-blind, randomized clinical trial evaluated the Circadian Rhythm for Mood (CRM) app's effectiveness in preventing mood episode recurrence in 93 adults with major depressive disorder (MDD) or bipolar disorder (BD). The active CRM group experienced a significantly lower recurrence rate compared to the sham app group, with an incidence rate ratio of 3.39.

Key findings

  • The active CRM group had a recurrence rate significantly lower than the sham group (incidence rate ratio=3.39).
  • Cumulative recurrent episode-days per person-year were greater in the sham group (duration rate ratio=2.76).
  • Time to recurrence was significantly longer in the active CRM group (hazard ratio=3.03).

Why it matters

Preventing mood episode recurrence is crucial for improving outcomes in patients with mood disorders. The CRM app offers a novel, scalable approach to enhance standard treatment and potentially reduce the burden of these conditions.

Source

PubMed · PMID 42337416

Published in Am J Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.